Bristol-Myers (BMY), Pfizer (PFE) Receive Approval for ELIQUIS in Japan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
ELIQUIS Receives FDA Approval in Reducing Certain Risks in Nonvalvular Atrial Fibrillation
January 2, 2013 8:03 AM ESTBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) approved ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Atrial fibrillation, the most common type of irregular heartbeat, affects approximately 5.8 million people in the U.S., and results in a five times greater risk of stroke. In the U.S., 15 percent of strokes are attributable to atrial fibrillation.
The approval of ELIQUIS offers patients with nonvalvular atrial fibrillation a... More
Pfizer (PFE) and Bristol-Meyers (BMY) win FDA approval for Eliquis
December 28, 2012 4:14 PM ESTPfizer, Inc. (NYSE: PFE) and Bristol-Meyers (NYSE: BMY) win FDA approval for Eliquis, according to Bloomberg headlines.... More
